Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Ph 2b Trial of IGV-001 in Newly Diagnosed GBM
“We are grateful for the support of our existing investors in this latest fundraising, which reflects their continued belief in the promise of IGV-001 for the thousands of patients facing a GBM diagnosis each year,” said John P. Furey, Chief Executive Officer. “The financing provides us with operating flexibility well beyond the readout of the top-line results of our Phase 2b trial, which we remain on track to report in mid-2025.”
Share:
More News
“We are excited to have restarted our Phase 2 study in presurgical triple-negative breast cancer. Triple-negative is a deadly and aggressive form of breast cancer, and patients having local disease currently undergo a harsh six-month regimen whereby a small percentage can die from the SOC before their surgery,” said Intensity
“TRAVERSE represents a potential breakthrough for both Allogene and the broader CAR T field,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene. “CAR T has transformed hematologic malignancies while solid tumors have remained one of the field’s most difficult challenges. When we designed ALLO-316 with the
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and
“As the data continue to mature, we are increasingly encouraged by the preliminary findings emerging from both cohorts, particularly the overall survival trends observed in the cohort with MGMT unmethylated glioblastoma,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “These findings further reinforce our belief that targeting mitochondrial